(Q24242728)

4

0 references

Anat Gafter-Gvili

3

0 references

Liat Vidal

5

0 references

Eyal Robenshtok

1

object named as

Eyal Robenshtok

0 references

Daphna Shefet

Cochrane Database of Systematic Reviews

2

object named as

Daphna Shefet

0 references

publication date

23 January 2008

0 references

published in

0 references

cites work

Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Evaluation of roxithromycin (RU-965) versus cephradine in pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

A comparative study of ofloxacin and amoxycillin/clavulanate in hospitalized patients with lower respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Sparfloxacin as alternative treatment to standard therapy for community-acquired bacteremic pneumococcal pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Azithromycin versus comparative therapy for the treatment of community acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

The FDA and the case of Ketek

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Guidelines for the management of adult lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

[Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

Ketek--the FDA perspective

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

Comparison of pefloxacin with ceftazidime in severe bronchopulmonary infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

The use of oral temafloxacin compared with a parenteral cephalosporin in hospitalized patients with pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

[Comparative study of the effectiveness of enoxacin and amoxicillin in bacterial pneumonia by a double blind method]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

[Comparison of DL-8280 and amoxicillin in the treatment of respiratory tract infections]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

Comparison of ciprofloxacin with imipenem in the treatment of severe pneumonia in hospitalised geriatric patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021

Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB3

7 January 2021